Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.3% – Here’s What Happened

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) traded down 7.3% during mid-day trading on Tuesday . The company traded as low as $50.48 and last traded at $49.3790. Approximately 97,929 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 359,392 shares. The stock had previously closed at $53.24.

Wall Street Analyst Weigh In

PLSE has been the topic of several recent research reports. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Pulse Biosciences has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Stock Down 7.0%

The firm has a 50 day moving average price of $38.45 and a two-hundred day moving average price of $28.25. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of -41.95 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky acquired 1,001 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were bought at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds have recently made changes to their positions in PLSE. Russell Investments Group Ltd. increased its stake in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter worth $28,000. Alliancebernstein L.P. grew its holdings in Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.